XOMA (XOMA)
(Delayed Data from NSDQ)
$24.05 USD
+0.07 (0.29%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $24.06 +0.01 (0.04%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Brokerage Reports
XOMA Corporation [XOMA]
Reports for Purchase
Showing records 201 - 220 ( 330 total )
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Emerging Pharmaceuticals - May and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q1 Financials: Non-Cash Items Not Material, In Our View;
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
We Believe Pyoderma Gangrenosum Phase 3 Design Reduces Clinical Risk
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
We Believe Pyoderma Gangrenosum Phase 3 Design Reduces Clinical Risk; Reiterate OUTPERFORM and $13 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Transferring Coverage
Provider: Roth Capital Partners, Inc.
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
April and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
We Recommend Buying XOMA As We Believe The Street Has Overlooked Neutrophilic Dermatoses Potential Value. Reiterate OUTPERFORM and $13 PT.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
We Recommend Buying XOMA As We Believe The Street Has Overlooked Neutrophilic Dermatoses Potential Value. Reiterate OUTPERFORM and $13 PT.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Corporate Update and 2013 Financials; EoA Is Out, but Neutrophilic Dermatoses Offsets - Reiterate OUTPERFORM and $13 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
February and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
February and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
We Presume Novartis $7MM Payment Was For Successful LFA102 Phase 1 Results. Reiterating OUTPERFORM and Converting to a $13 Twelve-Month Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan. 20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
The Top of 2014: - Choices Upcoming for Gevokizumab - Target to $10
Provider: Roth Capital Partners, Inc.
Analyst: HAZLETT R
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
January and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
January and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L